|
|
|
|
| LEADER |
03137nam a22005535i 4500 |
| 001 |
16025 |
| 003 |
DE-He213 |
| 005 |
20131010034020.0 |
| 007 |
cr nn 008mamaa |
| 008 |
131004s2013 gw | s |||| 0|eng d |
| 020 |
# |
# |
|a 9783642386640
|9 978-3-642-38664-0
|
| 024 |
7 |
# |
|a 10.1007/978-3-642-38664-0
|2 doi
|
| 050 |
# |
4 |
|a RM1-950
|
| 072 |
# |
7 |
|a MMG
|2 bicssc
|
| 072 |
# |
7 |
|a MED071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615
|2 23
|
| 100 |
1 |
# |
|a Humbert, Marc.
|e editor.
|
| 245 |
1 |
0 |
|a Pharmacotherapy of Pulmonary Hypertension
|c edited by Marc Humbert, Oleg V. Evgenov, Johannes-Peter Stasch.
|h [electronic resource] /
|
| 264 |
# |
1 |
|a Berlin, Heidelberg :
|b Springer Berlin Heidelberg :
|b Imprint: Springer,
|c 2013.
|
| 300 |
# |
# |
|a IX, 576 p. 66 illus., 56 illus. in color.
|b online resource.
|
| 336 |
# |
# |
|a text
|b txt
|2 rdacontent
|
| 337 |
# |
# |
|a computer
|b c
|2 rdamedia
|
| 338 |
# |
# |
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
# |
# |
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
# |
|a Handbook of Experimental Pharmacology,
|v 218
|x 0171-2004 ;
|
| 505 |
0 |
# |
|a Preface.-�Part I. Pulmonary hypertension: conceptual bases of the disease. Pulmonary hypertension: definition, classification, and epidemiology. Pulmonary hypertension: pathophysiology and signalling pathways. Pulmonary hypertension: pathology. Pulmonary hypertension: biomarkers. Pulmonary hypertension: animal models -- Part II. Pulmonary hypertension: established therapies. General supportive care. Calcium channel blockers. Prostacyclins. Endothelin receptor antagonists. Phosphodiesterase 5 inhibitors -- Part III. Pulmonary hypertension: novel pathways and emerging therapies � � Soluble guanylate cyclase stimulators. Therapeutics targeting dysregulated redox equilibrium and endothelial dysfunction (NOXs, sGC activators, GSNOR). Rho-kinase inhibitors. Serotonin transporters and serotonin receptors. PDGF inhibitors. Novel anti-proliferative strategies beyond imatinib. Immunosuppressive agents. Vasoactive peptides. Inhibitors of cGMP/cAMP metabolism (MRP4, MRP5, PDE1). Old targets re-visited. Stem cells and cell based therapy -- Part IV. Conclusions and Outlook. Pulmonary hypertension: evidence-based management in the modern era and future directions.
|
| 650 |
# |
0 |
|a Medicine.
|
| 650 |
# |
0 |
|a Medical laboratories.
|
| 650 |
# |
0 |
|a Toxicology.
|
| 650 |
# |
0 |
|a Pharmaceutical technology.
|
| 650 |
# |
0 |
|a Internal medicine.
|
| 650 |
# |
0 |
|a Pneumology.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Pharmaceutical Sciences/Technology.
|
| 650 |
2 |
4 |
|a Internal Medicine.
|
| 650 |
2 |
4 |
|a Pneumology/Respiratory System.
|
| 650 |
2 |
4 |
|a Laboratory Medicine.
|
| 650 |
2 |
4 |
|a Molecular Medicine.
|
| 700 |
1 |
# |
|a Evgenov, Oleg V.
|e editor.
|
| 700 |
1 |
# |
|a Stasch, Johannes-Peter.
|e editor.
|
| 710 |
2 |
# |
|a SpringerLink (Online service)
|
| 773 |
0 |
# |
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783642386633
|
| 830 |
# |
0 |
|a Handbook of Experimental Pharmacology,
|v 218
|x 0171-2004 ;
|
| 856 |
4 |
0 |
|u https://ezaccess.library.uitm.edu.my/login?url=http://dx.doi.org/10.1007/978-3-642-38664-0
|
| 912 |
# |
# |
|a ZDB-2-SBL
|
| 950 |
# |
# |
|a Biomedical and Life Sciences (Springer-11642)
|